India's first dengue vaccine approved India's drug regulatory authority has approved the Kydenga vaccine against dengue for use. The dengue vaccine has been approved in India. The vaccine named Kydenga, developed by a Japanese company against the dengue virus, has been approved for use in India. Developed by Japanese pharmaceutical company Takeda Pharmaceuticals , this vaccine has been approved by India's drug regulatory authority Central Drug Standards and Organization (CDACO). The Kydenga vaccine is said to provide protection against all four types of dengue virus serotypes 1, 2, 3 and 4 . Like the COVID-19 vaccine , it requires two doses. The second dose should be given three months after the first dose. This vaccine, which can be given to people aged 4 to 60 years, can also be given to those who have not had dengue. This vaccine, which is currently being produced in India, currently costs between Rs 6,000 and Rs 12,000 per dose . The price is expected to come down in ...
Why is breast cancer seen in young girls? After skin cancer, breast cancer is the most common cancer in women. This cancer, which is more common in women between the ages of 40 and 44, is now affecting younger women as well. According to a recent research, cases of breast cancer have been found in women aged 40 years or younger, but the risk of second primary breast cancer is decreasing. According to the American Cancer Society, the death rate from breast cancer has been decreasing continuously for the last few years. It is said that with regular checkups and proper treatment, the risk of dying from cancer is reduced. Also, with the help of early detection, fatal diseases like breast cancer can be avoided. What does the study say? The Harvard Public Health Breast Cancer Study included 1,297 women aged 40 or younger. From August 2006 to June 2015, zero to third stage cancer was diagnosed. In which a total of 685 women were found to have undergone primary surgery. They did a 'mastec...